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Genetically modified bacteriophages
Antonia P. Sagona,a Aurelija M. Grigonyte,ab Paul R. MacDonaldac and
Alfonso Jaramillo*ad
Phages or bacteriophages, viruses that infect and replicate inside bacteria, are the most abundant
microorganisms on earth. The realization that antibiotic resistance poses a substantial risk to the world’s
health and global economy is revitalizing phage therapy as a potential solution. The increasing ease by
which phage genomes can be modified, owing to the influx of new technologies, has led to an
expansion of their natural capabilities, and a reduced dependence on phage isolation from
environmental sources. This review will discuss the way synthetic biology has accelerated the
construction of genetically modified phages and will describe the wide range of their applications. It will
further provide insight into the societal and economic benefits that derive from the use of recombinant
phages in various sectors, from health to biodetection, biocontrol and the food industry.
Insight, innovation, integration
In this review, we address the technological advances of synthetic biology that enable the genetic engineering of bacteriophages. Further, we discuss the wide
spectrum of applications of genetically engineered bacteriophages.
1. Introduction
1.1 Why use recombinant phages?
Current advances in synthetic biology have facilitated the
rational design, modification and construction of recombinant
phages – that contain genetically engineered DNA and/or have
been through genetic recombination – enabling the extension
of their innate phenotypes. The host specificity of phages is
evolutionarily refined, with most phages targeting one species.
This host recognition specificity is conferred by receptor
binding domains (RBDs) that are found in either the tail-spike
or tail fiber protein assemblies of the virions. Many researchers
have altered the specificity of phages towards non-native hosts.1–6
In one such example, the host range of fd filamentous phage is
altered by fusing a RBD from another filamentous phage (IKe),
onto the infection-mediating protein of fd. Moving on to lytic
phages, a genetically engineered T4 phage repository, was curated
by randomizing the T4 RBD using polymerases with less fidelity
to PCR amplify non-conserved regions. The repository was found
to propagate in Yersinia ruckeri and Pseudomonas aeruginosa,
indicating that the host range of T4 had been re-directed from
its native Escherichia coli host.2 Similarly, T3 (which naturally
infects E. coli) and T7 phage (which infects E. coli and some
species of Yersinia) was assembled in Saccharomyces cerevisiae
with exogenous phage protein domains in order to alter its host
range. As a proof of concept, it was demonstrated that modified
T3 and T7 phage scaffolds could target pathogenic Yersinia and
Klebsiella bacteria respectively. In addition, Klebsiella phage
scaffolds were retargeted against Escherichia coli by swapping
their phage tail components.3
Recombinant phages also function as vehicles for anti-
microbials that are either incorporated into the phage7 or
attached to its surface.8 For instance, they have been used to
deliver light-activated antimicrobial agents (photosensitizers),
which are seen as promising alternatives to antibiotics for
treatment of common skin infections.9 Phages can also be
engineered to suppress host SOS DNA repair system, enhancing
the eﬀectiveness of broad-spectrum antibiotics in vitro.10
Understandably, a natural concern about using engineered
organisms is that the balance between natural phages in
the environment may be aﬀected. However, a recent study
illustrated that phages endowed with gain of function
mutations were out-competed by natural phages specific to
the same host, suggesting that engineered phage genomes
might not persist in the wild.11 Additionally, one strategy to
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commercialize phages is to re-engineer them to be non-replicative
or non-lytic.12,13
1.2 Synthetic biology technologies for phage engineering
Genome engineering. A wide range of genome engineering
methods have been applied to modify phage genomes and
provide the desired characteristics for diﬀerent applications.
For simplicity, we have divided the methods in the text into
in vitro and in vivo.
a. In vitro methods. Restriction endonuclease-based methods
have been used to construct recombinant genomes in vitro.
For instance, the genome of T7 was redesigned to remove
overlapping genetic elements among other modifications.
The new version of the genome (T7.1) is divided into 73 ‘parts’
belonging to six sections. The first two sections of T7.1 were
synthesized and shown to be viable.14
An additional, in vitro method is reported for the genetic
modification of lytic phages, called genome recombineering with
electroporated DNA (BRED), where they used the P1vir phage as a
proof of concept. BRED is based on the use of recombinases
(obtained from bacterial heterologous overexpression) to assemble
phage genomes from purified phage genome and given synthetic
DNA fragments.15 BRED has been recently used to genetically
modify a P1vir phage. Specifically, a copy of the mobile element
IS1 was removed from the genome of P1vir phage, with the use
of BRED.16
b. In vivo methods. In vivo methods have been used for
bacteriophage engineering involving marker-based or marker-less
selections of genetically modified bacteriophages. The most
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commonly used in vivo method is homologous recombination
(HR), where the sequence to be inserted is cloned into a vector
with flanking regions matching upstream and downstream of
phage genome sequence. Phage that has undergone HR can
then be selected from the phage population, with the methods
described below.
Marker-based selection methods exploit genes promoting
phage propagation. They could be genes encoded in the phage
genome or host factors required for phage propagation. For the
former, the gene has to be previously deleted from the genome,
where the phage may require a strain expressing such gene to
propagate. A first step would consist of the homologous
recombination of the insert and the gene marker. Later, a
marker-deficient strain could be used for selection. Alternatively,
a host factor can be used. For instance, in order to identify a
marker for T7 selection, E. coli BW25113 is screened for genes
that promote T7 phage growth, and these can be used as
selection markers when editing T7 phage genome. Two potential
genes are identified: cmk and trxA. Deletion of the trxA gene
appears to confer phage infection inhibition, whereas deletion
of the cmk gene in the bacterial host shows a lower eﬃciency
of plating of T7 bacteriophage in comparison to the control
bacteria. The reduced eﬃciency of plating, but not a complete
absence of plaques, indicates that despite the gene deletion,
some degree of T7 infection is obtained. These false positives can
be removed by serial dilutions. In this study the E. coli gene cmk,
which encodes for CMP/dCMP kinase, was inserted instead of
T7 gp5 by HR between wild-type T7 and a plasmid containing the
cmk gene. The plated recombined phage was shown to be
negative for growth on cells that were deficient in cmk, and
which did not contain a plasmid expressing gp5. This expected
phenotype was confirmed to be true at the genotypic level by
sequencing.17
False positives may occur in the marker-less selection
method, CRISPR/Cas.18 In a recent report, CRISPR/Cas system,
and specifically type I-E CRISPR/Cas system, was used to select
for engineered T7 bacteriophage (see Fig. 1). The T7 phage
genome was edited by homologous recombination and the
recombinant phages were selected by targeting wild-type
phages with the CRISPR/Cas system.19
In another report, in addition to using CRISPR/Cas for the
selection of engineered phage, CRISPR/Cas II-A system was
used to in vivo modify phage 2972. Phage genome editing
included gene exchange, point mutation and small or large
deletions. For the gene exchange, orf33 in the phage 2972 was
replaced with methyltransferase gene of the type II restriction/
modification (R/M) system LlaDCHI from L. lactis. Since the
results showed a successful gene swap and a fully functioning
methyltransferase it was concluded that the CRISPR/Cas
engineering system can be used for gene insertions into the
phage’s genome.20 CRISPR/Cas technology could be adapted to
other phage genomes.
In another example, bacteriophage engineering is accomplished
using an in vivo yeast platform as an alternative host for bacterio-
phage assembly. This platform is used to engineer phage
with novel host ranges by swapping viral tail fibre scaﬀolds.
Phage genomes are placed in Saccharomyces cerevisiae, allow gene
modifications and result in generation of engineered phage. Each
fragment of the phage genome is first amplified by PCR while
retaining a homologous overhang. First and last fragments of
the phage genome have a homology region with the yeast
artificial chromosome (YAC). All amplified phage genome
fragments as well as YAC are then transformed into yeast where
gap repair facilitated joining of all the fragments and the YAC
according to homology regions. After the purification of the
vector the phage can then be initiated to form functional phages
when transformed into bacteria. This yeast phage-engineering
platform has a great potential because any genomic loci can be
modified even by adding genes toxic to E. coli.3 One possible
inconvenience is that the phage may have repeats at their ends
(as it is the case for T7) and recombination may produce excision
of the phage from the vector. This may be overcome by including
a selective marker for yeast inside the phage genome.
Directed evolution methodologies. Directed evolution may
be used to alter and optimize bacteriophage genomes providing
a phenotypic or genotypic advantage in a given environment.
It is possible to evolve bacteriophages via serial passaging, or
Fig. 1 Summary of CRISPR/Cas system used for recombinant phage
selection via non-edited genome targeting. (a) The DNA of wild type
(WT) bacteriophage (in light blue) undergoes homologous recombination
following infection of the recombinant strain. The recombination strain
contains a plasmid with a sequence (in violet) with flanking homology
regions that replaces the WT phage genome sequence (in blue).
This infection results in mixed population of phage progeny, producing
recombinant phage (in violet) in addition to the WT phage (in blue). (b) The
selection strain contains a CRISPR-Cas system, which targets and cleaves
the WT sequence. Phages can still propagate in this strain, either because
of ineﬃciencies associated with the CRISPR machinery, or because they
contain one or more SNPs in the region targeted by the Cas-gRNA
complex (deemed escape mutants). (c) The CRISPR-Cas system does
not complex with the recombinant phage, resulting in relatively more
progeny.
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continuous culture in a bioreactor.21 This platform was used
to evolve lambda phage, which normally infects its host via
LamB protein receptor, to infect via a novel OmpF receptor.4
In another remarkable study, a phage was optimized by serial
passages in a living mouse providing a 13 000 fold greater
capacity of the phage to evade immune system and remain in
the circulatory system. This was a result of a single mutation
which led to amino acid substitution in the major lambda
phage capsid protein E.22
PACE (phage-assisted continuous evolution) combines
continuous culture with increased mutagenesis to accelerate
the evolution of M13 phagemids (non-replicative phages that
require a strain carrying a helper system). PACE is used to
evolve regulatory molecules rather than structural proteins in
the virion. This is done by removing an essential gene (gpIII)
from the phage and placing it, in an inactivated form, in the
host strain. The gene responsible for the initiation of the
evolution is introduced into the phage. The product of this
gene must activate gpIII to produce infectious progeny. It is
possible to use a similar methodology to evolve proteins from
the phage such as those conferring host specificity or involved
in replication.23 This method has been further expanded
to evolve biomolecules with altered or highly specific new
activities, using negative selection and modulation of selection
stringency.24
Phage display. Phage display is based on generating a library
of synthetic or natural peptides and then fusing them onto a
coat protein of a bacteriophage. Modified phages that bind
strongly to the ligand displayed are enriched via sequential
recovery from the surface and upon that they re-infect bacteria
to propagate and increase in number. Filamentous phages
M1325–33 and fd34–36 are the most commonly used phages for
phage display although T4,37,38 T739–43 and lambda44–47 phages
have also been used. Traditionally phage display has been used
for antibody production, proteomics,48 therapeutics, diagnostics
(specially for cancer applications), infectious diseases and drug
discovery.49,50 Phage display has also been used for epitope
mapping, a method to identify the epitope of the antigen that
interacts with an antibody. The identification of epitopes is
important for the development of diagnostic tools, vaccines
and new therapeutic targets.51,52 Additionally, phage display
has proven useful in targeting membrane receptors via the
identification of their agonists and antagonists, which present
biological applications as drugs for various diseases.53 Phage
display is also an excellent tool for the identification of protein–
protein interactions.54–57 Its biggest advantage, compared to
other methods established in the protein–protein interactions
field, is that highly diverse peptide libraries can be constructed at
low cost.56 These are some of the applications of phage display.
The list is even broader and even more applications are expected
to arise as the methodology evolves.58–67
2. Applications of engineered phages
Herein, we discuss how genetically modified phages (listed in
Table 1) are used in diﬀerent fields (presented in Fig. 2).
2.1 Therapeutic applications
Natural phages have multiple barriers that could prevent them
from being developed into viable phage therapeutic products.
Issues can arise both from their entry to mammalian cells and
from circumventing the immune response of the host. Modified
phages can be developed to avoid inactivation by the host defense
system and persist in the body, thus enhancing their therapeutic
potential.
In this section, examples of recombinant phages as therapeutic
agents for a variety of diseases are given. This includes phage
therapy in mammalian hosts as well as phages as lethal delivery
vehicles for prokaryotic hosts.
The T7 bacteriophage was genetically modified for a
potential therapy of hepatitis B. Globally HCC (hepatocellular
carcinoma) is the fifth most common cancer in men, and the
eighth most common in women, and it was estimated that
during the year 2000, more than 500 000 new cases arose.68
The first step of hepatitis B virus (HBV) infection is the inter-
action between a cell surface receptor and the HBV envelope
protein (specifically the PreS1 region). T7 phage was modified to
display polypeptides of varying length (up to fifty amino acids) of
the PreS1 region. This was achieved by fusing the peptides of
interest (PreSi region variants) to the C-terminus of the capsid
protein gp10B from T7. It was suggested that this system could be
enhanced by displaying amino acids of the first half of the PreS1
Table 1 Engineered bacteriophages and their applications
Engineered
bacteriophage Application
M13 Phage display,25–33 lethal delivery agent,83 engineered
protein purification,84 nanomaterials,87
vaccinology109,110
M13KE Pathogen detection100
T7 Phage display,39–43 gene therapy,69 biofilm control114
Lambda (l) Phage display44–47 vaccinology,46,70 biocontrol116
T4 Phage display,37,38 vaccinology72,112
fA1122 Pathogen detection106
A511 Pathogen detection104
HK620 Pathogen detection98
PBSPCA1 Agriculture108
fd Phage display,34–36 nanodevice fabrication and
bottom-up manufacturing85,86
Fig. 2 A schematic representation of the synthetic bacteriophage applications
discussed in this review.
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region, which would increase modified phage uptake and hence
the eﬃciency of desired gene transfer into the cell. This study
introduces T7 display as a model system for gene delivery into
mammalian host cells and elucidates recombinant phages
expand upon natural phage therapy.69
Another example of therapeutic bacteriophage applications in
mammalian systems is the display of a membrane glycoprotein,
of H5 influenza virus, on bacteriophage lambda major capsid
protein gpD.70 Here the lambda bacteriophage is assembled
without its major capsid protein first in vivo, and then a fusion
of gpD and H5 influenza membrane glycoprotein is added
in vitro. This approach can be used to ‘decorate’ gpD deficient
phage with recombinant gpD fused proteins (which are hetero-
logously expressed in insect cells). The recombinant phages bind
to the receptors on red blood cells and create a lattice structure of
interconnected virus and red blood cells. It is observed that two
H5 influenza-specific monoclonal antibodies inhibit the binding
of red blood cells to the recombinant phages. These modified
phagesmimic H5 influenza virus behavior by attaching to the red
blood cells; this could potentially be exploited for the detection of
influenza virus-specific antibodies in vaccine trials.71
T4 phage is another example of engineered phage use in
vaccinology. The outer capsid protein of T4 phage was fused to
a protective antigen from Bacillus anthracis, to develop a vaccine
for anthrax. The fusion protein was expressed in E. coli, purified,
and in vitro added to the assembled phage. The PA-T4 particles
presented immunogenicity in mice in the absence of an adjuvant.
This study provides a promising system for construction of
customized vaccines against anthrax.72
Phages target bacteria more specifically than most antibiotics,
and consequently have less eﬀect on the human gut microbiome.
However, lytic phages, whose concomitant cell lysis may result in
the release of toxic substances (endotoxins) have encouraged
the development of lysis-deficient phages. These lysis-deficient
phages can be engineered by harnessing the phage machinery
responsible for cell lysis. This consists of a membrane protein
(normally deemed, holin) and endolysin or murein hydrolase.
Holins form holes in the cell membrane, thus letting endolysin
cross the membrane and degrade the peptidoglycan layer of the
cell wall.73 An example of engineering a recombinant phage that
is lysis-deficient involves Staphylococcus aureus phage P954
where its endolysin gene was inactivated by a loss of function
insertion.74 Endolysin-deficient phages encoding lethal but
non-lytic proteins are able to kill bacteria while reducing the
endotoxin release.75 Engineered non-lytic phages have been
shown to be eﬃcient in treating mice infected with P. aeruginosa,
E. coli or S. aureus which present higher survival rates, due to
the lower levels of endotoxin release.13,74,76,77 Additionally,
filamentous phages (which do not lyse the host) have been
used for the specific delivery of lethal substances or genes to
the site of infection.78 Among possible genes, those encoding
for modified holin,79 lethal transcription regulator80 and addiction
toxins (which induce programmed cell death) have been
reported.81,82
Modified phage particles can also be used as lethal delivery
agents for eﬃcient pathogen killing. A recent example is the
engineering of the filamentous phage M13 to carry an integrin
binding peptide and a fragment of the polymorphic membrane
protein D from the sexually transmitted pathogen Chlamydia
trachomatis (Ct), as a possible way to eliminate Ct infection.
Based on this report, the engineered phage was able to signifi-
cantly reduce Ct infection in both primary endocervical and HeLa
cells, addressing the current lack of treatments against Chlamydia
trachomatis.83
2.2 Industrial applications
High-gradient magnetic fishing (HGMF) partially purifies target
products from heterogeneous bioprocess liquors. In HGMF,
the target product is captured using magnetic adsorbent
particles in combination with high-gradient magnetic separation
equipment. HGMF binding capacity of microbeads was increased
by placing an engineered M13 bacteriophage monolayer on a
superparamagnetic (SPM) core of microbeads. This was achieved
by genetic and chemical modification of the M13 coat proteins,
pIII (minor coat) and pVIII (major coat) respectively. pIII protein
was modified at its N-terminus to enable its binding onto
nitrilotriacetic acid or silica coated SPMs, respectively. pVIII
protein subunits of wild-type M13 were chemically cross-linked
to a carboxyl-functionalized bead permitting side-on linkage of
the phage to the SPMs. The phage-SPM particles, when used to
fish the desired antibodies, led to 490% purified product from
high protein solutions in one purification step.84
fd filamentous phage has been engineered to increase the
aﬃnity of gold (Au) to its protein coat. This was achieved by
substituting five amino acids on the N-terminal region of p8,
the fd phage’s major coat protein.85,86 These studies show how
recombinant phages can be coated with a metal of interest,
demonstrating the potential of recombinant phages as self-
assembling templates for applications in bottom up
manufacturing.
In addition, M13 filamentous bacteriophage has been used
as a scaﬀold for the self-assembly of cobalt manganese oxide
nanowires to make LiO2 battery electrodes. Here, the phage
coat protein gpVIII is modified to display peptides of negatively
charged amino acids, and is able to interact with cationic metal
precursors (such as cobalt and manganese) resulting in high
production yield oxides. These oxides formed LiO2 battery
electrodes which were more porous and had a higher specific
heat capacity in comparison to carbon electrodes.87
2.3 Biodetection applications
One area in which synthetic phages are proving useful is
biodetection, where one of their main advantages is that they
can be quickly amplified in the targeted live bacteria, compared
to PCR or antibody-wash detection systems (which subsequently
incur more false positives from the detection of dead bacteria).88
Early adoptions of biodetection with synthetic phages have
focused on the insertion of reporter genes into naturally isolated
phages.89–93 Most of these methods comprise of either inserting
luciferase genes into the phage genome, or of fusing fluorescent
proteins to the phage capsid, mimicking the engineering strategy
employed in phage display.94 It should be emphasized that these
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systems are far from just academic enquires. Sample6 recently
launched its DETECT/L kit on the back of luciferase-based
recombinant phage technologies.93 The kit correctly identifies
50 Listeria species, as well as correctly excluding 30 non-listeria
species that were subjected to testing. However, converting
luciferase-based assays to more optimal multiplex assays
(i.e. assays that detect more than one bacterial species in a given
sample) may not be straightforward,95 which is an issue that
could be circumvented by fluorescent-based reporter systems
with compatible emission and excitation wavelengths.96
The precision of phage host recognition has been explored for
pathogen detection from environmental samples. Water quality
control is one of the major concerns for public health as well
as marine environment, and rapid methods need to be developed
to allow accurate pathogen identification. One such method used
a phage-based fluorescent biosensor ‘phagosensor’ prototype
for enteric bacteria detection.97 In this system, the synthesis
of the fluorescent protein only occurs after it is delivered to
E. coli TD2158 by temperate bacteriophage HK620 carrying the
fluorescent gene.98 The recombinant phages were incubated with
the sample for one hour, followed by flow cytometry, which
allowed sensitive detection of environmental E. coli TD2158 strain
in diluted samples, and in mixed co-cultures. The established
template was also successfully adapted to phage P22 to detect
Salmonella enterica Typhimurium.99
Colorimetry is another method for detecting pathogenic
bacteria in water. In this instance, the target bacterial strain,
ER2378, is trapped on a syringe filter followed by infection of a
specific phage, M13KE.100 ER2378 is a lacZa-complementing
strain of E. coli that expresses the o-domain of the b-gal (oGal)
and the aGal peptide is cloned in an intergenetic region of the
M13KE genome.101,102 Upon aGal peptide delivery to the bacterial
strain, aGal is converted to the b-gal active form of aGal, which is
detectable by colorimetric assay.100
Another example of bacteriophage-based pathogen detection
is the high-intensity fluorophage that can detect Mycobacterium
tuberculosis.103 Phage A511 was modified to report cells of Listeria
genus upon synthesis of a bacterial luciferase gene. The modified
gene was placed downstream of the major capsid protein (cps)
and was expressed upon phage infection of Listeria cells.104
Yersinia pestis is the etiological agent of the plague, which
has seen a breakout of cases in America recently.105 To detect
Yersinia pestis in blood samples, a recombinant reporter phage
containing bacterial luxAB reporter genes was inserted in an
early-transcribed noncoding region of the plague-diagnostic
lytic phage fA1122 by homologous recombination. Upon infection
of Yersinia pestis with the recombinant fA1122, the biolumi-
nescent phenotype was observed after 10 to 15 min.106 In a
following study, the reporter phage was assessed as a diagnostic
tool for Yersinia pestis in samples taken directly from the blood.
Even though it displayed 100% inclusivity for Yersinia pestis,
some non-pestis Yersinia strains and Enterobacteriaceae also
showed signal transduction. The reporter phage demonstrated
rapid detection of antimicrobial susceptibility profiling upon
antibiotic incubation of the blood samples. As a consequence
these results suggest that the application of lytic reporter
phages to detect bacterial pathogens in blood samples could
reduce the time to diagnosis for patients aﬄicted with.107
Phage-reporter systems were also developed for agricultural
settings. Pseudomonas cannabina pv. alisalensis and Pseudomonas
syringae pv. maculicola are both causative agents for diseases of
Brassicaceae family. In a recent study, phage-based diagnostic
was developed to identify the cause of bacterial blight.
P. cannabina pv. alisalensis or PBSPCA1 phage was modified by
integration of bacterial luxAB genes in the place of nonessential
phoH gene using homologous recombination upon wild-type
PBSPCA1 phage infection of P. cannabina pv. alisalensis BS91
containing luxAB expression cassette. A successful detection of
Pseudomonas cannabina pv. alisalensis versus Pseudomonas syringae
pv. maculicola resulted in more than 100-fold increase in
bioluminescence within 4 hours of tissue harvesting.108
2.4 Veterinary applications
Genetically engineered phages have a wide range of applications
in veterinary science and medicine. In the vast majority of cases,
recombinant phages deliver antigens to be used for vaccination
against animal diseases.
Recombinant M13 bacteriophage has been used to vaccinate
pigs against the tapeworm Taenia solum, which causes cysticercosis,
a disease to which humans and pigs are susceptible. KETc1,
KETc12 and GK1 peptides were fused to coat protein gpVIII and
a recombinant antigen KETc7 was displayed on coat protein gpIII.
The pooled phages were successful in reducing the number
of cysts in the murine model (990 in mice receiving M13 vs.
338 immunized with the pool of recombinant phage). Preliminary
work demonstrated sporadic eﬀectiveness for a small sample
of pigs, but further studies were needed to corroborate this
evidence.109 Such a study was performed on a larger sample size,
and significantly reduced the occurrence of cysticercosis in
vaccinated pigs by 54.2%.110
Phages lambda and T4, as mentioned earlier in this review,
have been used to vaccinate against human diseases. In this
section, we briefly mention their application as possible vaccines
against pathogens that target animals. Recombinant lambda
phage can be used as a potential vaccine against porcine
Circovirus 2,46 a virus that causes post-weaning multisystemic
wasting syndrome (PMWS), and has proved costly in the swine
industry.111
In another study, the T4 bacteriophage was used to develop
a vaccine against infectious bursal disease virus (vvIBDV),
a virus that causes infectious bursal disease (IBD) in chickens.
Immunization of chickens with the recombinant T4-VP2 phage
resulted in no clinical death; however, some temporary bursal
damages were observed.112
2.5 Biocontrol applications
Biocontrol is the regulation of pest/pathogen levels by bio-
logical means; a strategy that is being progressively favored
by industry. One of the major problems in industrial processing
is biofilm formation, and this is especially apparent in food
industry.113 To this end, T7 bacteriophage was modified
to express dispersin B (DspB),114 an enzyme produced by
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Actinobacillus actinomycetemcomitans.115 DspB acts via b-1,6-N-
acetyl-D-glucosamine hydrolysis which disrupts biofilm formation
and integrity. DspB was placed downstream of capsid gene 10B
under the control of the strong T7 10 promoter. This allowed DspB
to be expressed intracellularly so that its release would occur
during cell lysis. The results showed that DspB expressing phage
was significantly more eﬀective at killing E. coli in comparison to
wild-type T7 and wild-type T3 bacteriophages, and that this phage
reduced the amount of biofilm by a factor of 2.6 in comparison to
non-engineered T7 control phage.114
In another study lambda phage was engineered to deliver
CRISPR/Cas system to sensitize bacteria with antibiotic resistance
genes. Once delivered to a pathogen, the CRISPR/Cas system
was transferable between bacterial hosts so that bacteria with
antibiotic genes would be outcompeted. In addition, pathogens
with acquired CRISPR/Cas were no longer susceptible to engineered
lytic phage infection. This system showed eﬀective reduction in
infections of antibiotic-resistant pathogens and thus oﬀering a
potential biocontrol system for hospital surface treatment.116
3. Discussion
Natural phages may be a solution to a myriad of issues in
agriculture, biocontrol, and medicine: in agriculture, they are
applied against plant infections; in biocontrol, in the protection
and control of crops and food products; and in medicine, a
number of trials have explored their safety and eﬃcacy.
Phage therapy has reached a critical juncture in its development.
Natural phages are, according to current legislature, unpatentable,
as they are no longer considered novel, having first been introduced
over a century ago.117 This prevents them from being commercially
viable in industry, especially for big pharma corporations that have
to undergo expensive clinical trials, and so is an impediment to
the development of infrastructure that can deliver treatments to
patients. The intellectual property of recombinant phages, on
the other hand, can be secured, thus overcoming these issues.
Yet recombinant phages do more than to provide opportunities
for profit; they extend upon natural phages by creating
additional functionalities (such as delivery of variety of cargos,
e.g. depolymerase114) as well as overcoming some of their
limitations.
One such limitation is that natural phages can induce a
mammalian immune response upon their entry, a response
that could be avoided by modifying the phage’s coat protein.
Nonetheless, in some instances, an overexcited immune
response is desired, for example, when developing vaccines
against viral particles. In the case of HBV, phage-displayed viral
peptides can evoke immune response, and help identify the
antibodies specific to these viral peptides.
Furthermore, by refactoring phage genomes,14 phages could
have their sequences rejigged to avoid host restriction systems, by
removing the palindromic sequences targeted by type II restriction
enzymes, or by appending peptides that inhibit the CRISPR/Cas
proteins. One can also envisage the swapping or addition of
exogenous endo/exonucleases to cleave host genomes faster.
Further work demonstrated that rational engineering of
tail fibres can change host tropism of bacteriophages1–6 and
pyocins118,119 (phage-like particles called bacteriocins, produced
by some strains of Pseudomonas aeruginosa for use in intra-
species warfare). Employing this in combination with directed
evolution, phage cocktails could be generated to target a given
pathogen through separate, or a combination of, receptors, and
adapted to circumvent the host-immune system. Importantly,
new techniques are constantly being developed in the fields of
genome engineering and gene synthesis, decreasing also the cost
of gene synthesis. It is expected that also because of that,
the engineering of recombinant bacteriophages will be further
facilitated and will enable the corresponding broadening of their
applications.
In summary, although there are still ethical, socio-economical,
and experimental issues to resolve, the groundwork of phages
appears promising, and will surely come to establish itself at the
forefront of personalized therapeutics and diagnostics.
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